Komori
Presentation materials on financial results4519CHUGAI PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Supplementary Materials for the Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [IFRS]

For the interim period of the fiscal year ending December 2026, revenue was ¥663.3 billion, operating profit was ¥319.6 billion, and profit for the period was ¥231.7 billion, all higher than in the same period of the previous year. Full-year forecasts are revenue of ¥1,345.0 billion, operating profit of ¥670.0 billion, and profit for the period of ¥485.0 billion.

Worth reading
44Recurring
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
14.7
Year-on-year change in revenue (%)
Wording
Avoiding a definitive answer
How definitive the wording is.

Contents of this document

Supplementary materials to the earnings reportSecond quarter (interim period) of the fiscal year ending December 20266 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales6,633 Hundred millions of yen+14.7%
Operating profit3,196 Hundred millions of yen+16.9%
Ordinary income3,292 Hundred millions of yen+21.1%
Net income2,317 Hundred millions of yen+19.2%
Gross Profit Margin70.3 %
Operating profit margin48.2 %
Selling, general and administrative expenses579 Hundred millions of yen
Results for the three months of the current quarter
Revenue
3,416 Hundred millions of yen+17.8%
Operating profit
1,609 Hundred millions of yen+17.7%
Quarterly profit
1,163 Hundred millions of yen+19.7%
Full-year earnings forecast
Revenue
13,450 Hundred millions of yen
Operating profit
6,700 Hundred millions of yen
Profit for the period
4,850 Hundred millions of yen
Core EPS
¥295
Annual Dividend
¥132
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
CHF
2026 full-year forecast¥184
EUR
2026 full-year forecast¥179
USD
2026 full-year forecast¥151
SGD
2026 full-year forecast¥119
Key KPIsA metric the company considers important as a management benchmark.
  • Core ROIC20.6 %
    Year on year against the same period last year20.1%
  • ROIC20 %
    Year on year against the same period last year20.2%
  • ROE11.4 %
    Year on year against the same period last year10.0%
  • Operating free cash flow3,157 Hundred millions of yen
    Year on year against the same period last year¥236.8 billion
  • Free cash flow2,270 Hundred millions of yen
    Year on year against the same period last year¥122.8 billion
  • CCC9.6 Month
    Year on year against the same period last year9.6 months
Number of employees
Number of Employees7,978 people
Capital expenditures
¥394 100 million January-June 2026, investment in property, plant and equipment
Annual Dividend
Annual dividend per share¥132
Interim¥66
End of period¥66
Payout ratio
44.7
Contents of this document
ItemDetails
Document typeSupplementary materials to the earnings report
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending December 2026
Net Sales6,633 Hundred millions of yen (YoY +14.7%)
Operating profit3,196 Hundred millions of yen (YoY +16.9%)
Ordinary income3,292 Hundred millions of yen (YoY +21.1%)
Net income2,317 Hundred millions of yen (YoY +19.2%)
Gross Profit Margin70.3 %
Operating profit margin48.2 %
Selling, general and administrative expenses579 Hundred millions of yen
Results for the three months of the current quarterRevenue 3,416 Hundred millions of yen (YoY +17.8%) / Operating profit 1,609 Hundred millions of yen (YoY +17.7%) / Quarterly profit 1,163 Hundred millions of yen (YoY +19.7%)
Full-year earnings forecastRevenue 13,450 Hundred millions of yen / Operating profit 6,700 Hundred millions of yen / Profit for the period 4,850 Hundred millions of yen / Core EPS ¥295 / Annual Dividend ¥132
Key KPIsIndicator name Core ROIC / Value 20.6 % / Year on year against the same period last year 20.1%, Indicator name ROIC / Value 20 % / Year on year against the same period last year 20.2%, Indicator name ROE / Value 11.4 % / Year on year against the same period last year 10.0%, Indicator name Operating free cash flow / Value 3,157 Hundred millions of yen / Year on year against the same period last year ¥236.8 billion, Indicator name Free cash flow / Value 2,270 Hundred millions of yen / Year on year against the same period last year ¥122.8 billion, Indicator name CCC / Value 9.6 Month / Year on year against the same period last year 9.6 months
Number of employeesNumber of Employees 7,978 people / Change during the period Not disclosed
Assumptions Underlying the Business OutlookCHF 2026 full-year forecast ¥184 / EUR 2026 full-year forecast ¥179 / USD 2026 full-year forecast ¥151 / SGD 2026 full-year forecast ¥119
Annual DividendAnnual dividend per share ¥132 / Interim ¥66 / End of period ¥66
Payout ratio44.7
Capital expenditures¥394 100 million (January-June 2026, investment in property, plant and equipment)
Items this document does not state (14)
Progress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&ANew initiatives

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The breakdown of revenue shows that sales of products manufactured overseas, royalty and profit-sharing income, and other operating income were higher than in the same period of the previous year. The materials do not explain in narrative form the specific background or factors behind these increases.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Supplementary Materials for the Consolidated Financial Results for the Second Quarter (Interim Period) of the Fiscal Year Ending December 2026 [IFRS] | CHUGAI PHARMACEUTICAL CO.,LTD. (4519) timely disclosure | Komori